reference/12190163

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12190163

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
issn	2045-2322
issueIdentifier	1
pageRange	12492-
publicationName	Scientific Reports
startingPage	12492
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_7345bb2c17d7a7dcada8f2e6aa9df6ca http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_74696b8fbacf2e7994d7f4f3cb791f5b http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f8509696cf2248ee4d8063e66b36699b
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_50a74889ab7508ed76ffcbe6ab306647 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_65262d273e9c69332d00f015ad5db745
bibliographicCitation	Kalscheuer S, Khanna V, Kim H, Li S, Sachdev D, DeCarlo A, Yang D, Panyam J. Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer. Scientific Reports. 2019 Aug 28;9(1):12492. doi: 10.1038/s41598-019-48993-6.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_396805437c006a269b083ee3a4945af3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5a313261928c2f369d4bb3669358cb8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_51ea106cedc7f38be7b0c71561674510 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8336-9457 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7651c238d81ead4ff551828c5d36143a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_72be3ad2704db24af7b62074932a5b8f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d99bee6cfff89e503529d71bc998f400 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8656-2244
date	2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/31462656 https://doi.org/10.1038/s41598-019-48993-6 https://pubmed.ncbi.nlm.nih.gov/PMC6713791
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39356 https://portal.issn.org/resource/ISSN/2045-2322
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer
discusses	http://id.nlm.nih.gov/mesh/M0195099 http://id.nlm.nih.gov/mesh/M0014578 http://id.nlm.nih.gov/mesh/M000626416 http://id.nlm.nih.gov/mesh/M0029407
hasSubjectTerm	http://purl.org/au-research/vocabulary/anzsrc-for/2008/11 http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112 http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1e8b2d9efd81025fcd21980393b8dd7c http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11451 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3339

Total number of triples: 46.